Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sanofi Announces FDA Extended Review Timeline For Tolebrutinib NDA In Secondary Progressive Multiple Sclerosis With Disability Accumulation

Author: Benzinga Newsdesk | September 22, 2025 01:28am

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Posted In: SNY